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mediating tumor suppression. It has 
been well documented that genotoxic 
stress, including telomere dysfunc-
tion, triggers apoptosis in some cell 
types, whereas in others senescence 
is the primary response. While such 
choices are not well understood, it is 
comforting that, in B cells, which pre-
fer apoptosis, senescence can act as 
a robust backup system. Finally, the 
possibility that oncogene- and telo-
mere-induced senescence may act 
as reinforcing, two-tiered defense 
systems, especially in human can-
cers, needs to be considered.
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Inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene occurs in most 
colorectal cancers. The proto-oncogene c-MYC was one of the first genes linked to APC inactiva-
tion, but the in vivo significance of c-MYC’s enhanced expression in intestinal cells with APC defects 
has been uncertain. Sansom et al. recently reported that targeted inactivation of c-Myc in murine 
intestinal epithelium potently inhibited phenotypical and transcriptional changes seen in Apc-defi-
cient intestinal epithelium. While these findings are very interesting, some questions remain about 
the assignment of c-Myc as the pre-eminent β-catenin-regulated gene in intestinal epithelium.The small intestine’s epithelial lining 
is characterized by invagination of the 
so-called crypts into surrounding tis-
sue and by the presence of finger-like 
protrusions (i.e., villi) extending into 
the lumen (Figure 1A). In the lower 
region of each crypt, there may be 
four to six stem cells (Marshman et 
al., 2002). Following their prolifera-
tive expansion in the crypt, progeni-
tors differentiate into enterocytes, 
goblet cells, and enteroendocrine 
cells as they migrate upward along the crypt-villus axis to populate the 
villus surface, or into Paneth cells as 
they migrate down to the base of the 
crypt. Enterocytes undergo apopto-
sis and/or are shed from the mucosal 
surface only days after their birth.
The β-catenin protein has previ-
ously been established to have a 
central role in regulating proliferation, 
differentiation, and migration in intes-
tinal epithelium (Batlle et al., 2002; 
Ireland et al., 2004; van de Wetering 
et al., 2002). Most of the cell’s pool of Cancer Ceβ-catenin is tethered to E-cadherin as 
an adherens junction component to 
mediate intercellular adhesion. A less 
abundant “free” pool of β-catenin can 
serve as a transcriptional coactivator 
upon its translocation to the nucleus 
and binding to DNA-binding proteins 
of the T cell factor (TCF) family (Fig-
ures 1B and 1C). In most cells, the 
free pool of β-catenin is tightly regu-
lated by a destruction complex com-
posed of the adenomatous polyposis 
coli (APC) and Axin tumor suppres-ll 11, May 2007 ©2007 Elsevier Inc. 391
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Previewsfigure 1. cell Proliferation and Differen-
tiation in the small Intestine, β-catenin-
Dependent Wnt signaling, and the 
Potential Role of MYc in Regulating 
β-catenin-Dependent Transcription in 
the Intestine
(A) Schematic structure of the architecture of 
the epithelium in the small intestine. A stem 
cell (or cells) near the base of the crypt gives 
rise to a rapidly dividing population that sub-
sequently differentiates into mature entero-
cytes, goblet cells, and enteroendocrine cells, 
which migrate up the crypt to populate the 
villus. After a life span of only a few days, en-
terocytes undergo apoptosis and are shed into 
the lumen of the gut. Wnt-β-catenin signaling 
is involved in the maintenance of a crypt pro-
genitor-like phenotype and differentiation of 
progenitor cells.
(B) β-catenin (β) is constitutively phosphory-
lated at several conserved serine/threonine 
residues in its amino-terminal domain by a de-
struction complex consisting of the APC, Axin, 
glycogen synthase kinase 3β (GSK3), and ca-
sein kinase Iα (CKIα) proteins. Phosphorylated 
β-catenin is targeted for ubiquitination and 
subsequent proteasomal degradation. Tran-
scription of potential β-catenin target genes 
is repressed due to binding of transcriptional 
repressors of the groucho/TLE family (TLE) to 
the DNA-binding proteins of the TCF (or lym-
phoid enhancer factor [LEF]) family.
(C) Upon binding of Wnt ligands to their cog-
nate receptor, consisting of a protein of the 
Frizzled protein family and the LDL-lipopro-
tein receptor-related protein 5/6 (LRP5/6) 
family, destruction of β-catenin is inhibited. 
β-catenin translocates to the nucleus, binds 
to TCF/LEF proteins, recruits coactivators, 
and activates its transcriptional target genes, 
such as c-Myc and CD44. Similarly, muta-
tional inactivation of APC or Axin, as well as 
mutation of conserved serine/threonine resi-
dues in β-catenin’s N terminus, leads to the 
accumulation of active β-catenin.
(D) Postulated models of β-catenin function 
in Apc-deficient intestinal epithelial cells. The 
upper model suggests that the altered phe-
notypes seen in Apc-deficient intestinal cells 
are attributable to β-catenin’s ability to alter 
transcription of a variety of downstream tar-
get genes. The lower model suggests that β-
catenin’s effects on cell phenotype are largely 
due to its ability to activate expression of c-
Myc and that c-Myc’s increased expression 
is essential in the regulation of downstream 
β-catenin target genes and the altered cell 
phenotype of Apc-deficient intestinal cells.sors, GSK3β, and other proteins. This 
complex promotes phosphorylation 
of β-catenin at several amino (N)-ter-
minal residues, which leads to ubiqui-
tination followed by proteasomal deg-
radation of phosphorylated β-catenin 
(Clevers, 2006). The destruction com-
plex is inhibited by binding of certain 
Wnt family ligands to transmembrane 
coreceptor complexes consisting of a 
frizzled family protein and an LRP5/6 
protein (Figure 1C). Wnt/β-catenin 392 Cancer Cell 11, May 2007 ©2007 Elsignaling has an essential role in stem 
cell regulation in intestinal tissues, as 
inactivation of the genes for β-catenin 
or Tcf-4, a major TCF protein in intes-
tinal cells, severely compromises 
crypt maintenance (Ireland et al., 
2004; Korinek et al., 1998). Mutational 
defects interfering with β-catenin’s 
degradation underlie development of 
a sizeable fraction of human cancers. 
APC gene defects are found in about 
75% of colorectal cancers, while sevier Inc.mutations in β-catenin’s N terminus 
are seen in 2%–5% of colorectal can-
cers. A net consequence of the APC 
and β-catenin defects is accumula-
tion of free β-catenin and constitu-
tive activation of a β-catenin/TCF 
transcriptional program. β-catenin 
dysregulation is found in the earliest 
stages of colorectal tumorigenesis in 
man and is inferred to have a key role 
in initiating development of adenoma-
tous lesions.
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ulated by β-catenin/TCF complexes 
have been of keen interest (Clevers, 
2006). Among the first described was 
the c-MYC gene (He et al., 1998). 
Data from chromatin immunoprecipi-
tation studies indicate that the c-Myc 
protein can bind to regulatory regions 
of up to 15% of all genes, leading 
to activation of certain genes and 
repression of others. The transcrip-
tional program regulated by c-Myc is 
context dependent, and the ultimate 
cellular response to elevated c-Myc 
levels can range from increased pro-
liferation to apoptosis (Dang et al., 
2006). In colorectal cancer cells, c-
Myc induction was associated with 
reduced expression of the cell-cycle 
inhibitor p21WAF1, apparently via c-
Myc’s function in repression of p21WAF1 
transcription (van de Wetering et al., 
2002). Because this study mainly 
analyzed c-Myc’s role in colorectal 
cancer cells growth in vitro and there 
are many other genes whose expres-
sion can be induced by β-catenin/
TCF, there has been obvious interest 
in assessing c-Myc’s function in Apc-
defective intestinal cells in vivo.
Studies of c-Myc’s function in 
intestinal epithelium were initially 
hampered in part by the fact that 
mice with constitutional defects in 
c-Myc die during embryogenesis. In 
a recent paper in the journal Nature, 
Sansom and colleagues used a pow-
erful conditional gene inactivation 
approach to explore c-Myc’s role in 
phenotypes seen in murine intestinal 
epithelial cells in which Apc is inac-
tivated (Sansom et al., 2007). The 
authors employed a transgenic model 
in which Cre recombinase expression 
is induced in small intestinal epithe-
lium by β-naphthoflavone treatment 
of mice, allowing targeting of floxed 
alleles in adult intestinal cells (Ire-
land et al., 2004). Prior work from the 
group had shown that biallelic inacti-
vation of Apc in intestinal epithelium 
was accompanied by accumulation 
of transcriptionally active β-catenin 
in cells, along with profound changes 
in cell differentiation, proliferation, 
and survival (Sansom et al., 2004). In 
contrast to the effects seen upon Apc 
inactivation in intestinal epithelium, where only c-Myc was inactivated, no 
major effects on crypt-villus architec-
ture were seen, and c-Myc deletion 
did not affect apoptotic rates (Mun-
can et al., 2006). The size of c-Myc-
deficient crypts was reported to be 
reduced secondary to a decrease in 
both cell number and cell size, per-
haps due to slower cell-cycle pro-
gression and cell division at a smaller 
cell size. In contrast to what had been 
suggested by in vitro findings (van de 
Wetering et al., 2002), no increased 
expression of p21WAF1 was observed 
in the c-Myc-deficient crypts. c-Myc-
deficient intestinal epithelial cells 
retained some ability to proliferate, 
but over time, c-Myc-deficient crypts 
were replaced via crypt fission events 
in neighboring crypts where somatic 
inactivation of c-Myc alleles had not 
been achieved.
In their most recent studies, San-
som and colleagues found that the 
increased proliferation and apopto-
sis seen in Apc-deficient crypts was 
nearly abolished when c-Myc was 
also deleted in parallel, implicating 
c-Myc function in the proliferative 
and apoptotic responses of Apc-
deficient intestinal cells (Sansom et 
al., 2007). The authors also observed 
that c-Myc inactivation rescued the 
altered cell migration and differen-
tiation seen in Apc-deficient crypts, 
resulting in essentially normal crypt-
villus architecture. Moreover, though 
the authors had found that somatic 
inactivation of Apc on its own leads 
to thousands of small lesions and 
multiple adenomas in the intestine, 
Apc and c-Myc double mutant cells 
were rapidly lost from the intestine, 
and no pathology was apparent. Not 
unexpectedly, c-Myc inactivation had 
no effect on the nuclear accumulation 
of β-catenin in Apc-deficient intesti-
nal cells. Hence, though β-catenin 
gained access to the nucleus, due to 
the lack of c-Myc function, β-catenin 
was apparently unable to induce 
changes in proliferation, differen-
tiation, migration, and apoptosis in 
the cells. To assess the importance 
of c-Myc in the global β-catenin/
TCF-regulated gene expression, the 
authors compared gene expression 
patterns in Apc-deficient crypts to Cancer Cethose in crypts deficient in both Apc 
and c-Myc. The studies revealed that 
about two-thirds of genes whose 
expression was activated in intestinal 
cells upon Apc inactivation were sig-
nificantly less activated when c-Myc 
was also inactivated. The authors 
conclude the dramatic morphological 
changes conferred by Apc inactiva-
tion in murine intestinal epithelium 
depend entirely on functional c-Myc. 
By extension, perhaps c-MYC func-
tion plays a similarly essential role in 
human colorectal cancer cells with 
APC or β-catenin defects.
The approach of Sansom et al. is a 
powerful one, and the authors’ data 
on the effects of combined c-Myc 
and Apc inactivation on intestinal 
crypt morphology, cell proliferation, 
and apoptosis are clear. However, is 
it possible that there might be some 
uncertainty about c-Myc’s presumed 
role as the pre-eminent downstream 
β-catenin/TCF-regulated gene in 
Apc-defective murine intestinal cells? 
Some uncertainty might arise from 
the possibility that c-Myc inactivation 
had powerful and potentially nonspe-
cific effects on intestinal cell pheno-
type not adequately captured by the 
assays and endpoints emphasized 
in the authors’ studies. For instance, 
while the authors found that c-Myc 
inactivation largely reversed the pro-
liferation, migration, differentiation, 
and apoptosis abnormalities seen 
in the first 4 days after acute inacti-
vation of Apc and c-Myc, the dou-
bly mutant intestinal cells were lost 
when intestinal tissues were studied 
at 20 days. It is not clear whether the 
apparent complete loss of intestinal 
cells lacking c-Myc reflects reduced 
proliferation or increased apoptosis 
of c-Myc-deficient transient amplify-
ing cell population in the crypt or pos-
sibly even a failure of c-Myc-deficient 
stem cells. Other issues impacting on 
interpretation of the results of San-
som et al. are that, besides Wnt sig-
nals and β-catenin/TCF complexes, 
the c-Myc gene has various other 
upstream signaling pathways that 
regulate its expression, and c-Myc 
function is a major determinant of 
biosynthetic capacity in the cell (Dang 
et al., 2006). Based on these consid-ll 11, May 2007 ©2007 Elsevier Inc. 393
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of c-Myc expression and function, 
rather than the more specific loss of 
β-catenin-dependent induction of c-
Myc, underlies the apparent pheno-
typic rescue of Apc-deficient intes-
tinal cells. A more precise approach 
than the one employed by the authors 
would be to specifically abrogate the 
β-catenin/TCF-mediated induction 
of c-Myc transcription, leaving all 
other aspects of c-Myc regulation 
and function intact. Though substan-
tial conceptual and technical chal-
lenges would need to be overcome 
to achieve this, one wonders whether 
the results obtained with such an 
approach might be quite different 
than those reported by Sansom et al. 
At this point, a skeptic might wonder 
whether the studies of Sansom et al. 394 Cancer Cell 11, May 2007 ©2007 Elrepresent the final word on c-Myc’s 
role in the Wnt/β-catenin/TCF path-
way or only the basis for a new attack 
on the question.
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